Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria

Further Publications Immunology

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Pediatr Allergy Immunol

Dekkers C, Alizadeh Aghdam M, Graaf M, Knulst AC, Meijer Y, van den Reek JMPA, Stadermann MB, Röckmann H

doi: 10.1111/pai.13426

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Int J Dermatol.

Syrigos N, Grapsa D, Zande M, Tziotou M, Syrigou E

doi: 10.1111/ijd.13935.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence

JAMA Dermatol.

Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, Abraham I, Lee CS

doi: 10.1001/jamadermatol.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Omalizumab Retreatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial

J Allergy Clin Immunol Pract.

Sussman G, Hébert J, Gulliver W, Lynde C, Yang WH, Papp K, Gooderham M, Chambenoit O, Khalil S, DeTakacsy F, Vieira A, Rihakova L

doi: 10.1016/j.jaip.2020.03.022.

Further Publications Dermatology

Response of Peripheral Blood Basophils in Subjects with Chronic Spontaneous Urticaria During Treatment with Omalizumab

J Allergy Clin Immunol

MacGlashan D Jr, Saini S, Schroeder JT

doi: 10.1016/j.jaci.2021.02.039

Further Publications Dermatology

Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis

JAMA Dermatol

Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S

doi: 10.1001/jamadermatol.2021.3237

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-blind Placebo-controlled Single Centre Study

J Allergy Clin Immunol Pract.

Maul JT, Distler M, Kolios A, Maul LV, Guillet C, Graf N, Imhof L, Lang C, Navarini AA, Schmid-Grendelmeier P

doi: 10.1016/j.jaip.2020.07.058.

Allergic Diseases

A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial

J Allergy Clin Immunol

Demoly P, Corren J, Creticos P, De Blay F, Gevaert P, Hellings P, Kowal K, Le Gall M, Nenasheva N, Passalacqua G, Pfaar O, Tortajada-Girbés M, Vidal C, Worm M, Casale TB

doi: 10.1016/j.jaci.2020.07.036

Allergic Diseases

A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial

J Allergy Clin Immunol.

Demoly P, Corren J, Creticos P, De Blay F, Gevaert P, Hellings P, Kowal K, Le Gall M, Nenasheva N, Passalacqua G, Pfaar O, Tortajada-Girbés M, Vidal C, Worm M, Casale TB

doi: 10.1016/j.jaci.

Related content

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence

Omalizumab Retreatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial

Response of Peripheral Blood Basophils in Subjects with Chronic Spontaneous Urticaria During Treatment with Omalizumab

Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis

Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-blind Placebo-controlled Single Centre Study

A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial

A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial